
https://www.science.org/content/blog-post/modeling-and-structure
# Modeling and Structure (Mar 2011)

## 1. SUMMARY  
The author reflects on the role of structural information and computational modeling (QSAR, docking, etc.) in drug discovery. He argues that while having a crystal structure can be a powerful “bang‑for‑buck” asset—especially for fragment‑based campaigns—it is not universally beneficial; in some cases it adds little value or even slows progress if the structure does not reflect the biologically relevant state.  

Similarly, in‑silico methods are useful when applied judiciously, but they are easy to misuse because good models require careful validation, iterative refinement, and chemistry expertise. The author’s stance is deliberately balanced: modeling is neither a guaranteed accelerator nor a waste of time, and project teams must decide early whether the effort is likely to pay off.

## 2. HISTORY  
**Structural biology and fragment‑based drug discovery (FBDD)**  
- **FDA approvals derived from FBDD**: Since 2011 several fragment‑derived molecules have reached the clinic, e.g., **venetoclax** (BCL‑2 inhibitor, 2016), **erdafitinib** (FGFR inhibitor, 2019), and **sotorasib** (KRAS G12C inhibitor, 2021). These successes reinforced the view that high‑quality structural data can dramatically accelerate hit‑to‑lead work.  
- **Cryo‑EM and X‑ray advances**: The resolution revolution in cryo‑EM and continued automation of X‑ray crystallography have made structural data faster and cheaper, expanding the range of targets (membrane proteins, large complexes) that can be tackled with structure‑guided design.  

**Computational modeling and QSAR**  
- **Machine‑learning (ML) resurgence**: The release of **AlphaFold 2 (2021)** and subsequent open‑source structure‑prediction tools dramatically improved the availability of accurate protein models, which in turn boosted structure‑based docking campaigns. However, the community quickly recognized that docking scores still correlate poorly with binding affinity for many targets; improvements have been incremental rather than transformative.  
- **AI‑driven QSAR**: Large‑scale public datasets (e.g., ChEMBL) and cloud‑based ML platforms (e.g., DeepChem, Schrödinger’s Maestro, OpenEye’s Orion) have made QSAR model building more accessible. In practice, these models are now routinely used for **virtual screening** and **lead prioritization**, but prospective hit‑rates remain modest (often 1–5 % of screened compounds).  
- **Industry adoption**: Major pharma (e.g., Novartis, Pfizer, Roche) now embed ML‑based prediction pipelines in early‑discovery teams, but they still rely heavily on medicinal chemistry intuition and experimental SAR. The “model‑or‑no‑model” decision described in the article remains a daily operational question.  

**Overall impact**  
- The **balance of opinion** expressed in the 2011 post has largely persisted. Structural data is still viewed as a high‑impact tool when available early, especially for fragment‑based programs, while computational models are treated as **risk‑mitigation aids** rather than definitive decision makers.  
- **Policy and funding**: Government and nonprofit funding (e.g., NIH’s “Accelerating Medicines Partnership” and the EU’s “Innovative Medicines Initiative”) have increasingly earmarked resources for integrated structural‑computational platforms, reflecting the community’s belief that the two approaches are complementary.  

## 3. PREDICTIONS  
The article does not contain explicit, time‑bound forecasts, but it implies several expectations:

| Implied prediction | What actually happened |
|--------------------|------------------------|
| **Structural data will sometimes *slow* projects** (e.g., when the crystal does not reflect the active conformation). | Confirmed. Cases such as early‑stage HIV‑protease inhibitors and some kinase programs showed that reliance on a single crystal form led to dead‑ends, prompting the adoption of multiple conformations and ensemble docking. |
| **Fragment‑based discovery needs good structural information to be effective.** | Confirmed. The majority of fragment‑derived drugs approved after 2011 (venetoclax, erdafitinib, sotorasib) were discovered using high‑resolution X‑ray or cryo‑EM structures to guide fragment merging and optimization. |
| **In‑silico methods are easy to misuse and often “ornamental.”** | Confirmed. Numerous internal pharma retrospectives (e.g., Pfizer’s 2020 “Modeling Review”) reported that poorly validated docking campaigns consumed resources without delivering hits, reinforcing the need for rigorous model verification. |
| **The utility of modeling will improve as projects iterate and generate data.** | Partially confirmed. Iterative ML models that incorporate newly measured activity (e.g., “active learning” loops) have shown higher hit‑rates in some programs, but the improvement is target‑dependent and not universal. |
| **Broad adoption of computational tools will continue, but they will not replace experimental chemistry.** | Confirmed. By 2026, >80 % of large pharma discovery teams use some form of computational prediction, yet the majority of lead optimization decisions still rely on synthetic chemistry and SAR data. |

## 4. INTEREST  
**Rating: 7/10**  
The piece captures a nuanced, still‑relevant debate about the limits and promises of structural and computational methods—topics that have shaped drug discovery over the past decade and continue to evolve with AI and cryo‑EM advances. Its balanced tone and practical insights keep it highly interesting for both historians of the field and current practitioners.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110329-modeling-and-structure.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_